高净化大麻在耐火和超耐火状态的有效性:一个案例系列
Giovanni Di Mauro1,2, Giovanni Vietri2, Loreta Quaranta3
1Epilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
CNS & neurological disorders drug targets
|June 24, 2024
概括
高净化大麻 (hpCBD) 在两个病例中有效治疗了耐火和超耐火状态的. 这种新型疗法可以在没有不良事件的情况下缓解发作,并在随访期间表现出持续的疗效.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐火状态 (RSE) 和超耐火状态 (SRSE) 是具有有限治疗选择的关键神经紧急情况.
- 目前对RSE和SRSE有效治疗的证据很少,这凸显了大量未满足的医疗需求.
研究的目的:
- 为了呈现两例RSE和SRSE的病例,有效地用高度净化的大麻二醇 (hpCBD) 治疗.
- 评估hpCBD的安全性和有效性,作为治疗状态的补充疗法.
主要方法:
- 两名被诊断患有耐火和超耐火状态的患者接受了通过鼻胃管给药的hpCBD治疗.
- 监测了临床结果,包括解决和不良事件.
- 对患者进行了6个月的随访,以评估长期疗效和安全性.
主要成果:
- 在这两种情况下,鼻胃用hpCBD成功解决了 status epilepticus.
- 在治疗期间没有报告任何不良事件.
- 在6个月的随访期间,两位患者在持续的hpCBD治疗下经历了持续的发作控制.
结论:
- 高净化大麻 (hpCBD) 显示出作为耐火和超耐火状态的附加疗法具有前途.
- 在随访期间维持hpCBD治疗可能对管理有好处.
- 需要进一步的研究和现实世界的数据来确认有效性,并了解与其他抗发作药物的相互作用.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385
Antiepileptic Drugs: Potassium Channel Activators
169
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
169
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31
Arteries of the Lower Limbs
187
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
187
Depolarizing Blockers: Pharmocokinetics
318
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
318


